{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:07:26Z","timestamp":1770480446264,"version":"3.49.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T00:00:00Z","timestamp":1317945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T00:00:00Z","timestamp":1317945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/eye.2011.246","type":"journal-article","created":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T18:53:58Z","timestamp":1318013638000},"page":"2-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Emerging techniques to treat corneal neovascularisation"],"prefix":"10.1038","volume":"26","author":[{"given":"J","family":"Menzel-Severing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,7]]},"reference":[{"key":"BFeye2011246_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","volume":"43","author":"P Lee","year":"1998","unstructured":"Lee P, Wang CC, Adamis AP . Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43: 245\u2013269.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2011246_CR2","first-page":"137","volume":"68","author":"IC Michaelson","year":"1948","unstructured":"Michaelson IC . The mode of development of the vascular system of the retina. With some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137.","journal-title":"Trans Ophthalmol Soc UK"},{"key":"BFeye2011246_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/bjo.33.4.248","volume":"33","author":"FW Campbell","year":"1949","unstructured":"Campbell FW, Michaelson IC . Blood-vessel formation in the cornea. Br J Ophthalmol 1949; 33: 248\u2013255.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2011246_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1242\/dev.105.3.473","volume":"105","author":"L Pardanaud","year":"1989","unstructured":"Pardanaud L, Yassine F, Dieterlen-Lievre F . Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 1989; 105: 473\u2013485.","journal-title":"Development"},{"key":"BFeye2011246_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/386671a0","volume":"386","author":"W Risau","year":"1997","unstructured":"Risau W . Mechanisms of angiogenesis. Nature 1997; 386: 671\u2013674.","journal-title":"Nature"},{"key":"BFeye2011246_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1242\/dev.125.4.725","volume":"125","author":"K Choi","year":"1998","unstructured":"Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G . A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725\u2013732.","journal-title":"Development"},{"key":"BFeye2011246_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81768-7","volume":"95","author":"N Hiraoka","year":"1998","unstructured":"Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ . Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365\u2013377.","journal-title":"Cell"},{"key":"BFeye2011246_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1083\/jcb.200302047","volume":"161","author":"H Gerhardt","year":"2003","unstructured":"Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163\u20131177.","journal-title":"J Cell Biol"},{"key":"BFeye2011246_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J . Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242\u2013248.","journal-title":"Nature"},{"key":"BFeye2011246_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27\u201331.","journal-title":"Nat Med"},{"key":"BFeye2011246_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.survophthal.2006.10.017","volume":"52","author":"M Dorrell","year":"2007","unstructured":"Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M . Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 2007; 52: S3\u2013S19.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2011246_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353\u2013364.","journal-title":"Cell"},{"key":"BFeye2011246_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P . Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389\u2013395.","journal-title":"Nat Med"},{"key":"BFeye2011246_CR14","first-page":"169","volume":"48","author":"PC Burger","year":"1983","unstructured":"Burger PC, Chandler DB, Klintworth GK . Corneal neovascularization as studied by scanning electron microscopy of vascular casts. Lab Invest 1983; 48: 169\u2013180.","journal-title":"Lab Invest"},{"key":"BFeye2011246_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcdb.2007.08.014","volume":"19","author":"DC Beebe","year":"2008","unstructured":"Beebe DC . Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. Semin Cell Dev Biol 2008; 19: 125\u2013133.","journal-title":"Semin Cell Dev Biol"},{"key":"BFeye2011246_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.matbio.2004.06.003","volume":"23","author":"T Pufe","year":"2004","unstructured":"Pufe T, Petersen WJ, Miosge N, Goldring MB, Mentlein R, Varoga DJ et al. Endostatin\/collagen XVIII--an inhibitor of angiogenesis--is expressed in cartilage and fibrocartilage. Matrix Biol 2004; 23: 267\u2013276.","journal-title":"Matrix Biol"},{"key":"BFeye2011246_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/nm1476","volume":"12","author":"M Yoshioka","year":"2006","unstructured":"Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 2006; 12: 1151\u20131159.","journal-title":"Nat Med"},{"key":"BFeye2011246_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0002-9394(14)70899-2","volume":"124","author":"MF Goldberg","year":"1997","unstructured":"Goldberg MF . Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am J Ophthalmol 1997; 124: 587\u2013626.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2011246_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.preteyeres.2010.01.002","volume":"29","author":"D Ellenberg","year":"2010","unstructured":"Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 2010; 29: 208\u2013248.","journal-title":"Prog Retin Eye Res"},{"key":"BFeye2011246_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.exer.2003.09.005","volume":"78","author":"E Gabison","year":"2004","unstructured":"Gabison E, Chang J-H, Hern\u00e1ndez-Quintela E, Javier J, Lu PC, Ye H et al. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004; 78: 579\u2013589.","journal-title":"Exp Eye Res"},{"key":"BFeye2011246_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","volume":"12","author":"JH Chang","year":"2001","unstructured":"Chang JH, Gabison EE, Kato T, Azar DT . Corneal neovascularization. Curr Opin Ophthalmol 2001; 12: 242\u2013249.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2011246_CR22","first-page":"264","volume":"104","author":"DT Azar","year":"2006","unstructured":"Azar DT . Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 264\u2013302.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"BFeye2011246_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bjo.2011.204701","volume":"96","author":"Claus Cursiefen","year":"2011","unstructured":"Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 2011; e-pub ahead of print 28 June 2011; doi:10.1136\/bjo.2011.204701.","journal-title":"British Journal of Ophthalmology"},{"key":"BFeye2011246_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","volume":"88","author":"Y Qazi","year":"2009","unstructured":"Qazi Y, Maddula S, Ambati BK . Mediators of ocular angiogenesis. J Genet 2009; 88: 495\u2013515.","journal-title":"J Genet"},{"key":"BFeye2011246_CR25","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","volume":"117","author":"B Bachmann","year":"2010","unstructured":"Bachmann B, Taylor RS, Cursiefen C . Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010; 117: 1300\u20131305.e7.","journal-title":"Ophthalmology"},{"key":"BFeye2011246_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","volume":"22","author":"C Cursiefen","year":"2003","unstructured":"Cursiefen C, Chen L, Dana MR, Streilein JW . Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003; 22: 273\u2013281.","journal-title":"Cornea"},{"key":"BFeye2011246_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4049\/jimmunol.0903180","volume":"184","author":"T Dietrich","year":"2010","unstructured":"Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010; 184: 535\u2013539.","journal-title":"J Immunol"},{"key":"BFeye2011246_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0065-2423(10)50006-4","volume":"50","author":"M Rajappa","year":"2010","unstructured":"Rajappa M, Saxena P, Kaur J . Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 2010; 50: 103\u2013121.","journal-title":"Adv Clin Chem"},{"key":"BFeye2011246_CR29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0092-8674(93)90573-9","volume":"72","author":"B Millauer","year":"1993","unstructured":"Millauer B, Wizigmann-Voos S, Schn\u00fcrch H, Martinez R, M\u00f8ller NP, Risau W et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835\u2013846.","journal-title":"Cell"},{"key":"BFeye2011246_CR30","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N . Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306\u20131309.","journal-title":"Science"},{"key":"BFeye2011246_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O\u2019Shea KS et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439\u2013442.","journal-title":"Nature"},{"key":"BFeye2011246_CR32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/0006-291X(92)90483-2","volume":"187","author":"BI Terman","year":"1992","unstructured":"Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579\u20131586.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFeye2011246_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME . Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27: 331\u2013371.","journal-title":"Prog Retin Eye Res"},{"key":"BFeye2011246_CR34","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1084\/jem.178.6.2077","volume":"178","author":"A Kaipainen","year":"1993","unstructured":"Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico MG, Terman BI et al. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med 1993; 178: 2077\u20132088.","journal-title":"J Exp Med"},{"key":"BFeye2011246_CR35","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","volume":"19","author":"R Bin\u00e9truy-Tournaire","year":"2000","unstructured":"Bin\u00e9truy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000; 19: 1525\u20131533.","journal-title":"EMBO J"},{"key":"BFeye2011246_CR36","first-page":"18","volume":"39","author":"S Amano","year":"1998","unstructured":"Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP . Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39: 18\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00417-007-0683-5","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, Cursiefen C . Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 2008; 246: 115\u2013119.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2011246_CR38","first-page":"581","volume":"39","author":"T Cheng","year":"1998","unstructured":"Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM . Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat M\u00fcller cells. Invest Ophthalmol Vis Sci 1998; 39: 581\u2013591.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.0.CO;2-1","volume":"24","author":"MA Behzadian","year":"1998","unstructured":"Behzadian MA, Wang XL, Al-Shabrawey M, Shabrawey M, Caldwell RB . Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia 1998; 24: 216\u2013225.","journal-title":"Glia"},{"key":"BFeye2011246_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1006\/exer.1999.0790","volume":"70","author":"A Kvanta","year":"2000","unstructured":"Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B . Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 70: 419\u2013428.","journal-title":"Exp Eye Res"},{"key":"BFeye2011246_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1076\/ceyr.23.1.1.5422","volume":"23","author":"V Mastyugin","year":"2001","unstructured":"Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML . Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 2001; 23: 1\u201310.","journal-title":"Curr Eye Res"},{"key":"BFeye2011246_CR42","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1083\/jcb.101.6.2330","volume":"101","author":"VP Terranova","year":"1985","unstructured":"Terranova VP, DiFlorio R, Lyall RM, Hic S, Friesel R, Maciag T . Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330\u20132334.","journal-title":"J Cell Biol"},{"key":"BFeye2011246_CR43","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1073\/pnas.86.19.7311","volume":"86","author":"D Gospodarowicz","year":"1989","unstructured":"Gospodarowicz D, Abraham JA, Schilling J . Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311\u20137315.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye2011246_CR44","first-page":"323","volume":"31","author":"G Soubrane","year":"1990","unstructured":"Soubrane G, Jerdan J, Karpouzas I, Fayein NA, Glaser B, Coscas G et al. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 1990; 31: 323\u2013333.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","volume":"16","author":"M Presta","year":"2005","unstructured":"Presta M, Dell\u2019Era P, Mitola S, Moroni E, Ronca R, Rusnati M . Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159\u2013178.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFeye2011246_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MOH.0b013e3282f97d98","volume":"15","author":"M Murakami","year":"2008","unstructured":"Murakami M, Simons M . Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 2008; 15: 215\u2013220.","journal-title":"Curr Opin Hematol"},{"key":"BFeye2011246_CR47","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2353\/ajpath.2009.080452","volume":"174","author":"T Onguchi","year":"2009","unstructured":"Onguchi T, Han KY, Chang J-H, Azar DT . Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization. Am J Pathol 2009; 174: 1564\u20131571.","journal-title":"Am J Pathol"},{"key":"BFeye2011246_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737\u2013744.","journal-title":"Nat Cell Biol"},{"key":"BFeye2011246_CR49","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1126\/science.277.5323.242","volume":"277","author":"P Lindahl","year":"1997","unstructured":"Lindahl P, Johansson BR, Lev\u00e9en P, Betsholtz C . Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242\u2013245.","journal-title":"Science"},{"key":"BFeye2011246_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1172\/JCI200318549","volume":"112","author":"A Abramsson","year":"2003","unstructured":"Abramsson A, Lindblom P, Betsholtz C . Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112: 1142\u20131151.","journal-title":"J Clin Invest"},{"key":"BFeye2011246_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.drup.2004.09.001","volume":"7","author":"J Glade Bender","year":"2004","unstructured":"Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ . Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004; 7: 289\u2013300.","journal-title":"Drug Resist Updat"},{"key":"BFeye2011246_CR52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","volume":"150","author":"JJ P\u00e9rez-Santonja","year":"2010","unstructured":"P\u00e9rez-Santonja JJ, Campos-Mollo E, Lled\u00f3-Riquelme M, Javaloy J, Ali\u00f3 JL . Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010; 150: 519\u2013528.e1.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2011246_CR53","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.1073\/pnas.122109599","volume":"99","author":"RP Visconti","year":"2002","unstructured":"Visconti RP, Richardson CD, Sato TN . Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 2002; 99: 8219\u20138224.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye2011246_CR54","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-10-0213","volume":"9","author":"A Coxon","year":"2010","unstructured":"Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1\/2-neutralizing peptibody. Mol Cancer Ther 2010; 9: 2641\u20132651.","journal-title":"Mol Cancer Ther"},{"key":"BFeye2011246_CR55","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature05249","volume":"443","author":"BK Ambati","year":"2006","unstructured":"Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993\u2013997.","journal-title":"Nature"},{"key":"BFeye2011246_CR56","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/bjo.2006.107417","volume":"91","author":"BK Ambati","year":"2007","unstructured":"Ambati BK, Patterson E, Jani P, Jenkins C, Higgins E, Singh N et al. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol 2007; 91: 505\u2013508.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2011246_CR57","doi-asserted-by":"publisher","first-page":"11405","DOI":"10.1073\/pnas.0506112103","volume":"103","author":"C Cursiefen","year":"2006","unstructured":"Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006; 103: 11405\u201311410.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye2011246_CR58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/35107085","volume":"414","author":"Y Makino","year":"2001","unstructured":"Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550\u2013554.","journal-title":"Nature"},{"key":"BFeye2011246_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1126\/science.285.5425.245","volume":"285","author":"DW Dawson","year":"1999","unstructured":"Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245\u2013248.","journal-title":"Science"},{"key":"BFeye2011246_CR60","first-page":"154","volume":"7","author":"PC Karakousis","year":"2001","unstructured":"Karakousis PC, John SK, Behling KC, Surace EM, Smith JE, Hendrickson A et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 2001; 7: 154\u2013163.","journal-title":"Mol Vis"},{"key":"BFeye2011246_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000111153","volume":"40","author":"O Abdiu","year":"2008","unstructured":"Abdiu O, Van Setten G . Antiangiogenic activity in tears: presence of pigment-epithelium-derived factor. New insights and preliminary results. Ophthalmic Res 2008; 40: 16\u201318.","journal-title":"Ophthalmic Res"},{"key":"BFeye2011246_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","volume":"79","author":"MS O\u2019Reilly","year":"1994","unstructured":"O\u2019Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315\u2013328.","journal-title":"Cell"},{"issue":"Pt 3","key":"BFeye2011246_CR63","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1042\/bj3390705","volume":"339","author":"SS Twining","year":"1999","unstructured":"Twining SS, Wilson PM, Ngamkitidechakul C . Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1alpha and -1beta. Biochem J 1999; 339 ( Pt 3): 705\u2013712.","journal-title":"Biochem J"},{"key":"BFeye2011246_CR64","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/archopht.120.8.1063","volume":"120","author":"BK Ambati","year":"2002","unstructured":"Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120: 1063\u20131068.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2011246_CR65","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1038\/sj.onc.1206816","volume":"22","author":"T Tonini","year":"2003","unstructured":"Tonini T, Rossi F, Claudio PP . Molecular basis of angiogenesis and cancer. Oncogene 2003; 22: 6549\u20136556.","journal-title":"Oncogene"},{"key":"BFeye2011246_CR66","first-page":"2517","volume":"42","author":"H-C Lin","year":"2001","unstructured":"Lin H-C, Chang J-H, Jain S, Gabison EE, Kure T, Kato T et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42: 2517\u20132524.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR67","doi-asserted-by":"publisher","first-page":"29568","DOI":"10.1074\/jbc.274.41.29568","volume":"274","author":"MS O\u2019Reilly","year":"1999","unstructured":"O\u2019Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA . Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999; 274: 29568\u201329571.","journal-title":"J Biol Chem"},{"key":"BFeye2011246_CR68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0945-053X(03)00005-2","volume":"22","author":"LC Armstrong","year":"2003","unstructured":"Armstrong LC, Bornstein P . Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22: 63\u201371.","journal-title":"Matrix Biol"},{"key":"BFeye2011246_CR69","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1167\/iovs.03-0940","volume":"45","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45: 1117\u20131124.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR70","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1006\/bbrc.1995.2780","volume":"217","author":"OV Volpert","year":"1995","unstructured":"Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995; 217: 326\u2013332.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFeye2011246_CR71","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1096\/fj.04-2209fje","volume":"19","author":"Y Oshima","year":"2005","unstructured":"Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 2005; 19: 963\u2013965.","journal-title":"FASEB J"},{"key":"BFeye2011246_CR72","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1167\/iovs.09-4571","volume":"51","author":"C-T Lin","year":"2010","unstructured":"Lin C-T, Hu F-R, Kuo K-T, Chen YM, Chu HS, Lin YH et al. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci 2010; 51: 6277\u20136285.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR73","first-page":"2148","volume":"41","author":"CT Pillai","year":"2000","unstructured":"Pillai CT, Dua HS, Hossain P . Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000; 41: 2148\u20132153.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bjo.87.1.101","volume":"87","author":"C Cursiefen","year":"2003","unstructured":"Cursiefen C, Hofmann-Rummelt C, K\u00fcchle M, Schl\u00f6tzer-Schrehardt U . Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol 2003; 87: 101\u2013106.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2011246_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/lrb.2008.6348","volume":"6","author":"B Regenfuss","year":"2008","unstructured":"Regenfuss B, Bock F, Parthasarathy A, Cursiefen C . Corneal (lymph)angiogenesis--from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 2008; 6: 191\u2013201.","journal-title":"Lymphat Res Biol"},{"issue":"4","key":"BFeye2011246_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archophthalmol.2011.42","volume":"129","author":"D Hos","year":"2011","unstructured":"Hos D, Saban DR, Bock F, Regenfuss B, Onderka J, Masli S et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol 2011; 129 (4): 445\u2013452.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2011246_CR77","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182\u20131186.","journal-title":"N Engl J Med"},{"key":"BFeye2011246_CR78","first-page":"1625","volume":"37","author":"BM Kenyon","year":"1996","unstructured":"Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D\u2019Amato RJ et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625\u20131632.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR79","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1167\/iovs.05-1494","volume":"47","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA . Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci 2006; 47: 462\u2013474.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR80","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.gt.3302653","volume":"13","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA . Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 2006; 13: 559\u2013562.","journal-title":"Gene Ther"},{"key":"BFeye2011246_CR81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nm731","volume":"8","author":"A Luttun","year":"2002","unstructured":"Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831\u2013840.","journal-title":"Nat Med"},{"key":"BFeye2011246_CR82","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1026574416001","volume":"19","author":"R Auerbach","year":"2000","unstructured":"Auerbach R, Akhtar N, Lewis RL, Shinners BL . Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000; 19: 167\u2013172.","journal-title":"Cancer Metastasis Rev"},{"key":"BFeye2011246_CR83","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","volume":"115","author":"SW Kim","year":"2008","unstructured":"Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI . The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115: e33\u2013e38.","journal-title":"Ophthalmology"},{"key":"BFeye2011246_CR84","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1167\/iovs.07-1418","volume":"49","author":"CQ Yu","year":"2008","unstructured":"Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI . Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 2008; 49: 3870\u20133878.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR85","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","volume":"116","author":"C Cursiefen","year":"2009","unstructured":"Cursiefen C, Bock F, Horn FK, Kruse FE, Seitz B, Borderie V et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009; 116: 1630\u20131637.","journal-title":"Ophthalmology"},{"key":"BFeye2011246_CR86","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1167\/iovs.05-0105","volume":"46","author":"C Andrieu-Soler","year":"2005","unstructured":"Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen F . Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 2005; 46: 4072\u20134078.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR87","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00347-010-2262-0","volume":"108","author":"F Bock","year":"2011","unstructured":"Bock F, Regenfu\u00df B, Cursiefen C . [Antiangiogenic therapy at the ocular surface: When, what and why?]. Ophthalmologe 2011; 108: 230\u2013236.","journal-title":"Ophthalmologe"},{"key":"BFeye2011246_CR88","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2005.04.108","volume":"332","author":"N Singh","year":"2005","unstructured":"Singh N, Macnamara E, Rashid S, Ambati J, Kontos CD, Higgins E et al. Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun 2005; 332: 194\u2013199.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFeye2011246_CR89","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1167\/iovs.02-0853","volume":"44","author":"RC Murthy","year":"2003","unstructured":"Murthy RC, McFarland TJ, Yoken J, Chen S, Barone C, Burke D et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44: 1837\u20131842.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR90","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/104303401750270959","volume":"12","author":"CM Lai","year":"2001","unstructured":"Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12: 1299\u20131310.","journal-title":"Hum Gene Ther"},{"key":"BFeye2011246_CR91","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/sj.gt.3301695","volume":"9","author":"YK Lai","year":"2002","unstructured":"Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE . Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002; 9: 804\u2013813.","journal-title":"Gene Ther"},{"key":"BFeye2011246_CR92","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1167\/iovs.04-1172","volume":"46","author":"N Singh","year":"2005","unstructured":"Singh N, Amin S, Richter E, Rashid S, Scoglietti V, Jani PD et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 2005; 46: 1647\u20131652.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR93","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1167\/iovs.06-0853","volume":"48","author":"PD Jani","year":"2007","unstructured":"Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2030\u20132036.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR94","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000072143","volume":"35","author":"W-Z Yu","year":"2003","unstructured":"Yu W-Z, Li X-X, She H-C, He PY, Dong JQ, Rui M et al. Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 2003; 35: 239\u2013246.","journal-title":"Ophthalmic Res"},{"key":"BFeye2011246_CR95","first-page":"210","volume":"9","author":"SJ Reich","year":"2003","unstructured":"Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210\u2013216.","journal-title":"Mol Vis"},{"key":"BFeye2011246_CR96","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","volume":"165","author":"B Kim","year":"2004","unstructured":"Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004; 165: 2177\u20132185.","journal-title":"Am J Pathol"},{"key":"BFeye2011246_CR97","first-page":"1975","volume":"42","author":"SU Stechschulte","year":"2001","unstructured":"Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci 2001; 42: 1975\u20131979.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR98","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/02713680500330512","volume":"30","author":"C-N Kuo","year":"2005","unstructured":"Kuo C-N, Yang L-C, Wu P-C, Kuo HK, Kuo CJ, Tai MH . Dehydrated form of plasmid expressing basic fibroblast growth factor-polyethylenimine complex is a novel and accurate method for gene transfer to the cornea. Curr Eye Res 2005; 30: 1015\u20131024.","journal-title":"Curr Eye Res"},{"key":"BFeye2011246_CR99","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1124\/jpet.105.088211","volume":"315","author":"A Mezentsev","year":"2005","unstructured":"Mezentsev A, Mastyugin V, Seta F, Ashkar S, Kemp R, Reddy DS et al. Transfection of cytochrome P4504B1 into the cornea increases angiogenic activity of the limbal vessels. J Pharmacol Exp Ther 2005; 315: 42\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFeye2011246_CR100","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J . Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273\u2013286.","journal-title":"Nat Rev Drug Discov"},{"key":"BFeye2011246_CR101","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.2910150209","volume":"15","author":"R Auerbach","year":"1975","unstructured":"Auerbach R, Arensman R, Kubai L, Folkman J . Tumor-induced angiogenesis: lack of inhibition by irradiation. Int J Cancer 1975; 15: 241\u2013245.","journal-title":"Int J Cancer"},{"key":"BFeye2011246_CR102","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jnci\/52.2.413","volume":"52","author":"MA Gimbrone","year":"1974","unstructured":"Gimbrone MA, Cotran RS, Leapman SB, Folkman J . Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413\u2013427.","journal-title":"J Natl Cancer Inst"},{"key":"BFeye2011246_CR103","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545\u20132552.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2011246_CR104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jconrel.2007.05.041","volume":"124","author":"EA Klausner","year":"2007","unstructured":"Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV . Corneal gene therapy. J Controlled Release 2007; 124: 107\u2013133.","journal-title":"J Controlled Release"},{"key":"BFeye2011246_CR105","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/archopht.125.6.834","volume":"125","author":"JJ DeStafeno","year":"2007","unstructured":"DeStafeno JJ, Kim T . Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125: 834\u2013836.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2011246_CR106","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","volume":"27","author":"HS Uy","year":"2008","unstructured":"Uy HS, Chan PS, Ang RE . Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008; 27: 70\u201373.","journal-title":"Cornea"},{"key":"BFeye2011246_CR107","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, K\u00f6nig Y, Kruse F, Baier M, Cursiefen C . Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246: 281\u2013284.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2011246_CR108","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/112067210901900530","volume":"19","author":"S Saxena","year":"2009","unstructured":"Saxena S, Kishore P, Pandey S, Khattri M, Kumar D . Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. Eur J Ophthalmol 2009; 19: 870\u2013872.","journal-title":"Eur J Ophthalmol"},{"key":"BFeye2011246_CR109","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/08820530902802013","volume":"24","author":"M Lim","year":"2009","unstructured":"Lim M, Jacobs DS, Rosenthal P, Carrasquillo KG . The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab. Semin Ophthalmol 2009; 24: 149\u2013155.","journal-title":"Semin Ophthalmol"},{"issue":"10","key":"BFeye2011246_CR110","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Y Koenig","year":"2009","unstructured":"Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C . Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247 (10): 1375\u20131382.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2011246_CR111","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","volume":"127","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda 2nd R et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127: 381\u2013389.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2011246_CR112","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","volume":"27","author":"PP Doctor","year":"2008","unstructured":"Doctor PP, Bhat PV, Foster CS . Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27: 992\u2013995.","journal-title":"Cornea"},{"key":"BFeye2011246_CR113","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A . Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27: 142\u2013147.","journal-title":"Cornea"},{"key":"BFeye2011246_CR114","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"M Erdurmus","year":"2007","unstructured":"Erdurmus M, Totan Y . Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1577\u20131579.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2011246_CR115","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","volume":"88","author":"AA Zaki","year":"2010","unstructured":"Zaki AA, Farid SF . Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 2010; 88: 868\u2013871.","journal-title":"Acta Ophthalmol"},{"key":"BFeye2011246_CR116","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/ICO.0b013e31820cd3f4","volume":"30","author":"JH Jeong","year":"2011","unstructured":"Jeong JH, Chun YS, Kim ES, Kim JC . Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection. Cornea 2011; 30: 1071\u20131077.","journal-title":"Cornea"},{"key":"BFeye2011246_CR117","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","volume":"247","author":"PI Vassileva","year":"2009","unstructured":"Vassileva PI, Hergeldzhieva TG . Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1701\u20131706.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2011246_CR118","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","volume":"28","author":"JY Oh","year":"2009","unstructured":"Oh JY, Kim MK, Wee WR . Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009; 28: 1070\u20131073.","journal-title":"Cornea"},{"key":"BFeye2011246_CR119","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","volume":"30","author":"SN Yeung","year":"2011","unstructured":"Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR . Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 2011; 30: 1110\u20131114.","journal-title":"Cornea"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/eye2011246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/eye2011246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/eye2011246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:21:26Z","timestamp":1650352886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2011246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,7]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["BFeye2011246"],"URL":"https:\/\/doi.org\/10.1038\/eye.2011.246","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,7]]},"assertion":[{"value":"13 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}